Anti-VEGF Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2032

Description

Persistence Market Research has recently released a comprehensive report on the worldwide market for anti-VEGF therapies. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global anti-VEGF market from 2025 to 2032. The anti-VEGF market is positioned for significant growth, with a projected CAGR of 4.0% from 2025 to 2032, indicating a market value increase from USD 25.2 billion in 2025 to USD 33.1 billion by 2032.

Key Insights:

Anti-VEGF Market Size (2025E): USD 25.2 Bn
Projected Market Value (2032F): USD 33.1 Bn
Global Market Growth Rate (CAGR 2025 to 2032): 4.0%

Anti-VEGF Market - Report Scope:

Anti-VEGF (vascular endothelial growth factor) therapies are pharmaceutical treatments designed to inhibit the activity of VEGF proteins, which play a critical role in abnormal blood vessel formation associated with various diseases. These therapies are widely used in ophthalmology for treating conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion, as well as in oncology for managing certain cancers. The anti-VEGF market caters to hospitals, specialty clinics, and ambulatory surgical centers, offering a range of drugs delivered through intravitreal injections and systemic administration. Market growth is driven by the rising prevalence of retinal disorders, increasing geriatric population, and ongoing advancements in biologics and targeted therapies.

Market Growth Drivers:

The global anti-VEGF market is propelled by several key factors, including the growing incidence of vision-threatening disorders such as wet age-related macular degeneration and diabetic macular edema. The expanding elderly population worldwide significantly contributes to rising demand for anti-VEGF treatments. Advancements in biologic drug development, including longer-acting formulations and biosimilars, enhance treatment efficacy and patient compliance. Additionally, improved healthcare infrastructure, greater awareness of early diagnosis, and increased access to advanced therapies in emerging markets support market expansion.

Market Restraints:

Despite promising growth prospects, the anti-VEGF market faces challenges related to high treatment costs and limited accessibility in low- and middle-income regions. Frequent dosing requirements for certain therapies may reduce patient adherence and increase healthcare burden. Stringent regulatory requirements for biologics approval and the complexity of manufacturing biosimilars pose barriers to market entry. Furthermore, potential side effects associated with intravitreal injections and competition from alternative treatment approaches may hinder market growth.

Market Opportunities:

The anti-VEGF market presents significant growth opportunities driven by technological innovations and expanding therapeutic applications. The development of long-acting formulations, sustained-release implants, and gene therapies offers potential for reduced dosing frequency and improved patient outcomes. Increasing research in combination therapies and expanding indications in oncology and ophthalmology further broaden the market scope. Strategic collaborations between pharmaceutical companies, research institutions, and healthcare providers, along with growing investment in biosimilar development, are expected to create new avenues for growth and enhance market competitiveness.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the anti-VEGF market globally?
Which product types and applications are driving anti-VEGF adoption across different therapeutic areas?
How are technological advancements reshaping the competitive landscape of the anti-VEGF market?
Who are the key players contributing to the anti-VEGF market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global anti-VEGF market?

Competitive Intelligence and Business Strategy:

Leading players in the global anti-VEGF market, including Roche Holding AG, Regeneron Pharmaceuticals, and Novartis AG, focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest heavily in R&D to develop advanced biologics, biosimilars, and extended-duration therapies that improve treatment outcomes and patient convenience. Partnerships with research organizations and healthcare providers support clinical development and global distribution. Moreover, emphasis on expanding indications, improving affordability, and strengthening regulatory approvals fosters market growth and enhances competitiveness in the evolving anti-VEGF landscape.

Key Companies Profiled:

Pfizer Inc.
Bayer AG
Novartis AG
Sanofi SA
Exelixis Inc.
Eisai Co. Ltd.
Amgen Inc.
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Amneal Pharmaceuticals Inc.
Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Takeda Pharmaceutical Co. Ltd.
Sino Biopharma
HUTCHMED

Anti-VEGF Market Research Segmentation:

By Drug

Small Molecules
Biologics

By Type

VEGF-A Inhibitors
VEGF-B Inhibitors
VEGF-C Inhibitors
Placenta Growth Factor Inhibitors

By Disease Indication:

Oncology
Hematology Disorders
Ophthalmology Disorders

By Distribution Channel:

Hospitals
Specialty Clinics
Mail Order Pharmacies

By Region

North America

Latin America

Europe

South Asia

East Asia

Oceania

Middle East and Africa

Product Code: PMRREP33422

1. Executive Summary

1.1. Global Anti-VEGF Market Snapshot 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
1.3. Key Market Trends
1.4. Industry Developments and Key Market Events
1.5. Demand Side and Supply Side Analysis
1.6. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definitions
2.2. Value Chain Analysis
2.3. Macro-Economic Factors
- 2.3.1. Global GDP Outlook
- 2.3.2. Global GDP Outlook
- 2.3.3. Global economic Growth Forecast
- 2.3.4. Global Urbanization Growth
- 2.3.5. Other Macro-economic Factors
2.4. Forecast Factors - Relevance and Impact
2.5. COVID-19 Impact Assessment
2.6. PESTLE Analysis
2.7. Porter's Five Forces Analysis
2.8. Geopolitical Tensions: Market Impact
2.9. Regulatory and Technology Landscape

3. Market Dynamics

3.1. Drivers
3.2. Restraints
3.3. Opportunities
3.4. Trends

4. Price Trend Analysis, 2019 - 2032

4.1. Region-wise Price Analysis
4.2. Price by Segments
4.3. Price Impact Factors

5. Global Anti-VEGF Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

5.1. Key Highlights
5.2. Global Anti-VEGF Market Outlook: Drug
- 5.2.1. Introduction/Key Findings
- 5.2.2. Historical Market Size (US$ Bn) Analysis by Drug, 2019-2024
- 5.2.3. Current Market Size (US$ Bn) Forecast, by Drug, 2025-2032
  - 5.2.3.1. Small Molecules
    - 5.2.3.1.1. Pazopanib
    - 5.2.3.1.2. Sunitinib
    - 5.2.3.1.3. Sorafenib
    - 5.2.3.1.4. Regorafenib
    - 5.2.3.1.5. Cabozantinib
    - 5.2.3.1.6. Lenvatinib
  - 5.2.3.2. Biologics
    - 5.2.3.2.1. Bevacizumab
    - 5.2.3.2.2. Aflibercept
    - 5.2.3.2.3. Ramucirumab
- 5.2.4. Market Attractiveness Analysis: Drug
5.3. Global Anti-VEGF Market Outlook: Type
- 5.3.1. Introduction/Key Findings
- 5.3.2. Historical Market Size (US$ Bn) Analysis by Type, 2019-2024
- 5.3.3. Current Market Size (US$ Bn) Forecast, by Type, 2025-2032
  - 5.3.3.1. VEGF-A Inhibitors
  - 5.3.3.2. VEGF-B Inhibitors
  - 5.3.3.3. VEGF-C Inhibitors
  - 5.3.3.4. Placenta Growth Factor Inhibitors
- 5.3.4. Market Attractiveness Analysis: Type
5.4. Global Anti-VEGF Market Outlook: Disease Indication
- 5.4.1. Introduction/Key Findings
- 5.4.2. Historical Market Size (US$ Bn) Analysis by Disease Indication, 2019-2024
- 5.4.3. Current Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
  - 5.4.3.1. Oncology
  - 5.4.3.2. Hematology Disorders
  - 5.4.3.3. Ophthalmology Disorders
- 5.4.4. Market Attractiveness Analysis: Disease Indication
5.5. Global Anti-VEGF Market Outlook: Distribution Channel
- 5.5.1. Introduction/Key Findings
- 5.5.2. Historical Market Size (US$ Bn) Analysis by Distribution Channel, 2019-2024
- 5.5.3. Current Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
  - 5.5.3.1. Hospitals
  - 5.5.3.2. Specialty Clinics
  - 5.5.3.3. Mail Order Pharmacies
- 5.5.4. Market Attractiveness Analysis: Distribution Channel

6. Global Anti-VEGF Market Outlook: Region

6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis by Region, 2019-2024
6.3. Current Market Size (US$ Bn) Forecast, by Region, 2025-2032
- 6.3.1. North America
- 6.3.2. Europe
- 6.3.3. East Asia
- 6.3.4. South Asia & Oceania
- 6.3.5. Latin America
- 6.3.6. Middle East & Africa
6.4. Market Attractiveness Analysis: Region

7. North America Anti-VEGF Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

7.1. Key Highlights
7.2. Pricing Analysis
7.3. North America Market Size (US$ Bn) Forecast, by Country, 2025-2032
- 7.3.1. U.S.
- 7.3.2. Canada
7.4. North America Market Size (US$ Bn) Forecast, by Drug, 2025-2032
- 7.4.1. Small Molecules
  - 7.4.1.1. Pazopanib
  - 7.4.1.2. Sunitinib
  - 7.4.1.3. Sorafenib
  - 7.4.1.4. Regorafenib
  - 7.4.1.5. Cabozantinib
  - 7.4.1.6. Lenvatinib
- 7.4.2. Biologics
  - 7.4.2.1. Bevacizumab
  - 7.4.2.2. Aflibercept
  - 7.4.2.3. Ramucirumab
7.5. North America Market Size (US$ Bn) Forecast, by Type, 2025-2032
- 7.5.1. VEGF-A Inhibitors
- 7.5.2. VEGF-B Inhibitors
- 7.5.3. VEGF-C Inhibitors
- 7.5.4. Placenta Growth Factor Inhibitors
7.6. North America Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
- 7.6.1. Oncology
- 7.6.2. Hematology Disorders
- 7.6.3. Ophthalmology Disorders
7.7. North America Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
- 7.7.1. Hospitals
- 7.7.2. Specialty Clinics
- 7.7.3. Mail Order Pharmacies

8. Europe Anti-VEGF Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

8.1. Key Highlights
8.2. Pricing Analysis
8.3. Europe Market Size (US$ Bn) Forecast, by Country, 2025-2032
- 8.3.1. Germany
- 8.3.2. Italy
- 8.3.3. France
- 8.3.4. U.K.
- 8.3.5. Spain
- 8.3.6. Russia
- 8.3.7. Rest of Europe
8.4. Europe Market Size (US$ Bn) Forecast, by Drug, 2025-2032
- 8.4.1. Small Molecules
  - 8.4.1.1. Pazopanib
  - 8.4.1.2. Sunitinib
  - 8.4.1.3. Sorafenib
  - 8.4.1.4. Regorafenib
  - 8.4.1.5. Cabozantinib
  - 8.4.1.6. Lenvatinib
- 8.4.2. Biologics
  - 8.4.2.1. Bevacizumab
  - 8.4.2.2. Aflibercept
  - 8.4.2.3. Ramucirumab
8.5. Europe Market Size (US$ Bn) Forecast, by Type, 2025-2032
- 8.5.1. VEGF-A Inhibitors
- 8.5.2. VEGF-B Inhibitors
- 8.5.3. VEGF-C Inhibitors
- 8.5.4. Placenta Growth Factor Inhibitors
8.6. Europe Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
- 8.6.1. Oncology
- 8.6.2. Hematology Disorders
- 8.6.3. Ophthalmology Disorders
8.7. Europe Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
- 8.7.1. Hospitals
- 8.7.2. Specialty Clinics
- 8.7.3. Mail Order Pharmacies

9. East Asia Anti-VEGF Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

9.1. Key Highlights
9.2. Pricing Analysis
9.3. East Asia Market Size (US$ Bn) Forecast, by Country, 2025-2032
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. South Korea
9.4. East Asia Market Size (US$ Bn) Forecast, by Drug, 2025-2032
- 9.4.1. Small Molecules
  - 9.4.1.1. Pazopanib
  - 9.4.1.2. Sunitinib
  - 9.4.1.3. Sorafenib
  - 9.4.1.4. Regorafenib
  - 9.4.1.5. Cabozantinib
  - 9.4.1.6. Lenvatinib
- 9.4.2. Biologics
  - 9.4.2.1. Bevacizumab
  - 9.4.2.2. Aflibercept
  - 9.4.2.3. Ramucirumab
9.5. East Asia Market Size (US$ Bn) Forecast, by Type, 2025-2032
- 9.5.1. VEGF-A Inhibitors
- 9.5.2. VEGF-B Inhibitors
- 9.5.3. VEGF-C Inhibitors
- 9.5.4. Placenta Growth Factor Inhibitors
9.6. East Asia Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
- 9.6.1. Oncology
- 9.6.2. Hematology Disorders
- 9.6.3. Ophthalmology Disorders
9.7. East Asia Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
- 9.7.1. Hospitals
- 9.7.2. Specialty Clinics
- 9.7.3. Mail Order Pharmacies

10. South Asia & Oceania Anti-VEGF Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

10.1. Key Highlights
10.2. Pricing Analysis
10.3. South Asia & Oceania Market Size (US$ Bn) Forecast, by Country, 2025-2032
- 10.3.1. India
- 10.3.2. Southeast Asia
- 10.3.3. ANZ
- 10.3.4. Rest of SAO
10.4. South Asia & Oceania Market Size (US$ Bn) Forecast, by Drug, 2025-2032
- 10.4.1. Small Molecules
  - 10.4.1.1. Pazopanib
  - 10.4.1.2. Sunitinib
  - 10.4.1.3. Sorafenib
  - 10.4.1.4. Regorafenib
  - 10.4.1.5. Cabozantinib
  - 10.4.1.6. Lenvatinib
- 10.4.2. Biologics
  - 10.4.2.1. Bevacizumab
  - 10.4.2.2. Aflibercept
  - 10.4.2.3. Ramucirumab
10.5. South Asia & Oceania Market Size (US$ Bn) Forecast, by Type, 2025-2032
- 10.5.1. VEGF-A Inhibitors
- 10.5.2. VEGF-B Inhibitors
- 10.5.3. VEGF-C Inhibitors
- 10.5.4. Placenta Growth Factor Inhibitors
10.6. South Asia & Oceania Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
- 10.6.1. Oncology
- 10.6.2. Hematology Disorders
- 10.6.3. Ophthalmology Disorders
10.7. South Asia & Oceania Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
- 10.7.1. Hospitals
- 10.7.2. Specialty Clinics
- 10.7.3. Mail Order Pharmacies

11. Latin America Anti-VEGF Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

11.1. Key Highlights
11.2. Pricing Analysis
11.3. Latin America Market Size (US$ Bn) Forecast, by Country, 2025-2032
- 11.3.1. Brazil
- 11.3.2. Mexico
- 11.3.3. Rest of LATAM
11.4. Latin America Market Size (US$ Bn) Forecast, by Drug, 2025-2032
- 11.4.1. Small Molecules
  - 11.4.1.1. Pazopanib
  - 11.4.1.2. Sunitinib
  - 11.4.1.3. Sorafenib
  - 11.4.1.4. Regorafenib
  - 11.4.1.5. Cabozantinib
  - 11.4.1.6. Lenvatinib
- 11.4.2. Biologics
  - 11.4.2.1. Bevacizumab
  - 11.4.2.2. Aflibercept
  - 11.4.2.3. Ramucirumab
11.5. Latin America Market Size (US$ Bn) Forecast, by Type, 2025-2032
- 11.5.1. VEGF-A Inhibitors
- 11.5.2. VEGF-B Inhibitors
- 11.5.3. VEGF-C Inhibitors
- 11.5.4. Placenta Growth Factor Inhibitors
11.6. Latin America Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
- 11.6.1. Oncology
- 11.6.2. Hematology Disorders
- 11.6.3. Ophthalmology Disorders
11.7. Latin America Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
- 11.7.1. Hospitals
- 11.7.2. Specialty Clinics
- 11.7.3. Mail Order Pharmacies

12. Middle East & Africa Anti-VEGF Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

12.1. Key Highlights
12.2. Pricing Analysis
12.3. Middle East & Africa Market Size (US$ Bn) Forecast, by Country, 2025-2032
- 12.3.1. GCC Countries
- 12.3.2. South Africa
- 12.3.3. Northern Africa
- 12.3.4. Rest of MEA
12.4. Middle East & Africa Market Size (US$ Bn) Forecast, by Drug, 2025-2032
- 12.4.1. Small Molecules
  - 12.4.1.1. Pazopanib
  - 12.4.1.2. Sunitinib
  - 12.4.1.3. Sorafenib
  - 12.4.1.4. Regorafenib
  - 12.4.1.5. Cabozantinib
  - 12.4.1.6. Lenvatinib
- 12.4.2. Biologics
  - 12.4.2.1. Bevacizumab
  - 12.4.2.2. Aflibercept
  - 12.4.2.3. Ramucirumab
12.5. Middle East & Africa Market Size (US$ Bn) Forecast, by Type, 2025-2032
- 12.5.1. VEGF-A Inhibitors
- 12.5.2. VEGF-B Inhibitors
- 12.5.3. VEGF-C Inhibitors
- 12.5.4. Placenta Growth Factor Inhibitors
12.6. Middle East & Africa Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
- 12.6.1. Oncology
- 12.6.2. Hematology Disorders
- 12.6.3. Ophthalmology Disorders
12.7. Middle East & Africa Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
- 12.7.1. Hospitals
- 12.7.2. Specialty Clinics
- 12.7.3. Mail Order Pharmacies

13. Competition Landscape

13.1. Market Share Analysis, 2024
13.2. Market Structure
- 13.2.1. Competition Intensity Mapping
- 13.2.2. Competition Dashboard
13.3. Company Profiles
- 13.3.1. Pfizer Inc.
  - 13.3.1.1. Company Overview
  - 13.3.1.2. Product Portfolio/Offerings
  - 13.3.1.3. Key Financials
  - 13.3.1.4. SWOT Analysis
  - 13.3.1.5. Company Strategy and Key Developments
- 13.3.2. Bayer AG
- 13.3.3. Novartis AG
- 13.3.4. Sanofi SA
- 13.3.5. Exelixis Inc.
- 13.3.6. Eisai Co. Ltd.
- 13.3.7. Amgen Inc.
- 13.3.8. F. Hoffmann-La Roche Ltd.
- 13.3.9. Eli Lilly and Company
- 13.3.10. Amneal Pharmaceuticals Inc.
- 13.3.11. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
- 13.3.12. Takeda Pharmaceutical Co. Ltd.
- 13.3.13. Sino Biopharma
- 13.3.14. HUTCHMED

14. Appendix

14.1. Research Methodology
14.2. Research Assumptions
14.3. Acronyms and Abbreviations